---
schema_version: "secwatch.filing_event.v1"
accession: "0000785161-23-000037"
form_type: "8-K"
ticker: "EHC"
cik: "0000785161"
company_name: "Encompass Health Corp"
filed_at: "2023-05-19T23:59:59+00:00"
generated_at: "2026-06-14T20:22:04.365646+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Encompass Health reiterates FY2023 guidance at investor meeting on May 22

## Summary
- Reaffirms FY2023 net operating revenue of $4,700M-$4,770M.
- Reaffirms FY2023 Adjusted EBITDA of $870M-$910M.
- Reaffirms FY2023 Adjusted EPS of $2.94-$3.23.
- CEO Mark Tarr and CFO Doug Coltharp to participate in investor meeting in Birmingham, AL on May 22, 2023.
- Guidance unchanged from April 27, 2023 earnings release and April 28, 2023 conference call.

## SEC filing metadata
- accession: 0000785161-23-000037
- form_type: 8-K
- ticker: EHC
- cik: 0000785161
- company_name: Encompass Health Corp
- filed_at: 2023-05-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/785161/000078516123000037/0000785161-23-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/785161/000078516123000037/ehc-20230519.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000785161-23-000037
- JSON: https://secwatch.observer/filing/0000785161-23-000037.json
- Plain text: https://secwatch.observer/filing/0000785161-23-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.